Key result
Daclizumab induction therapy was associated with a significantly lower 6-month prevalence of complications compared to historical OKT3 in heart transplant recipients (33% vs 55%, P=0.04).
Why the study?
Does daclizumab induction therapy improve safety and efficacy compared to OKT3 in pediatric and adult heart transplant recipients?
Population
80 pediatric and adult heart transplant recipients
Comparison
Daclizumab induction therapy vs OKT3 induction therapy (historical control group)
Design
Cohort
Follow-up
6 months
Authors
Loading...
May reduce complications versus historical OKT3; leaves open confirmation of safety and efficacy in randomized heart transplant trials.
Cohort (n=80)
Does daclizumab induction therapy improve safety and efficacy compared to OKT3 in pediatric and adult heart transplant recipients?
Absolute Event Rate: 33% vs 55%
p-value: p=0.04
Daclizumab induction therapy provides equivalent efficacy to OKT3 in heart transplant recipients but with a significantly lower rate of complications.
Chin et al. (2005) conducted a cohort in Heart transplantation (n=80). Daclizumab vs. OKT3 was evaluated on Six-month prevalence for complications (p=0.04). Daclizumab induction therapy was associated with a significantly lower 6-month prevalence of complications compared to historical OKT3 in heart transplant recipients (33% vs 55%, P=0.04).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: